A planar product for treatment of the urogenital tract having a proximal face and a distal face including at least one textile layer (4). The proximal face being coated with an antimicrobially and/or antiseptically effective agent. The planar product has a vitality of >80% after 18 h of incubation time in a Cytotoxicity Test described herein and an efficacy of <80% in a PI-MIA Test described herein.

The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual.

Described herein are antimicrobial (e.g., antibacterial, antiviral) compositions and methods of using such compositions.

The present invention relates to field of intravaginally applicable devices that release antiviral compounds. In particular, the present invention relates to vaginal rings comprising a matrix releasing at least one antivirally active compound, in particular anti-herpetic compound N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide (in the following also referred to as “Pritelivir”) or salts thereof. The present invention therefore relates to the treatment and prevention of herpes infections.

The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence.

The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments.

The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Disclosed herein are compositions, delivery devices and methods for feminine health. A delivery device for feminine health can include a feminine hygiene product including an absorbent substrate and a composition absorbed onto the absorbent substrate for placement against a vulva, inserted into a vagina, or both. The composition can include a continuous phase and a dispersed phase dispersed throughout the continuous phase forming a fluid suspension. The continuous phase can include a solvent of one or more essential oils, one or more lubricants, or a combination thereof. The continuous phase can include one or more solutes dissolved in the solvent including one or more fat-soluble vitamins. The dispersed phase can include a pH-balancing agent, a dietary mineral, an absorbent, one or more water-soluble vitamins, or a combination thereof.

The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual and for the treatment and prevention of recurrence in an HSV seropositive individual.

Provided herein are an intravaginal delivery device comprising a plurality of distinct hydrogel layers, and methods of using same for treating a disease or disorder.

A lubricant container configured to facilitate the delivery of lubricant steadily, over time, within a target cavity such as a vagina or anus is described. The container is composed of a soluble membrane or substrate configured to dissolve at or above body temperature. Subdivisions within the container, preferably established via dividers, are configured to contain differing types of lubricant which are to be released in differing stages after a certain amount of time has elapsed. Differing portions of the container, as well as the dividers, are preferably composed of substrate having differing densities and/or thicknesses to facilitate the time-delay function of the apparatus.

This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.